Post-hoc analyses of data from a phase 2 RCT in mild-to-moderate AD demonstrated that baseline plasma NfL predicted worsening clinical outcomes and MRI volumes over the 48-week trial better than baseline Aβ42/40, T-tau, P-tau181, or GFAP. The gene discussed is NEFL; the disease is Alzheimer disease.